Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. Its proprietary drug delivery platform technologies include an antibody transport vehicle and an enzyme transport vehicle designed to deliver large molecules across the blood-brain barrier (BBB). Its pipeline products are intended for the treatment of Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, multiple system atrophy, lysosomal storage disorder MPS II, neurodegeneration, amyotrophic lateral sclerosis and other indications. The company’s product pipeline include DNL201, DNL151, ATV:aSyn, for Parkinson’s disease, DNL747, ATV:Tau, ATV:TREM2, for Alzheimer’s disease; and CH1 and LF1, for neurodegeneration. It has development and commercialization rights to all of its programs, including the programs partnered with Takeda. The company operates in the UK and the US. Denali Therapeutics is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
161 Oyster Point Blvd, South San Francisco, California, 94080-1910
Website
www.denalitherapeutics.com
Telephone
1 650 8668548
No of Employees
445
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
DNLI (NASD)
Revenue (2022)
$330.5M
204.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
55.5%
(2022 vs 2021)
Market Cap*
$2.5B
Net Profit Margin (2022)
XYZ
85.4%
(2022 vs 2021)
* As of and is in US$
Denali Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Product Pipeline: |
| Lysosomal Function |
| LRRK2 |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Denali Therapeutics Inc | Eli Lilly and Co | Biogen Inc | Ionis Pharmaceuticals Inc | Prothena Corp Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Ireland |
| City | South San Francisco | Indianapolis | Cambridge | Carlsbad | Dublin |
| State/Province | California | Indiana | Massachusetts | California | - |
| No. of Employees | 445 | 43,000 | 7,570 | 927 | 173 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vicki Sato | Chairman | Executive Board | 2016 | 74 |
| Ryan J. Watts | President; Director; Chief Executive Officer | Executive Board | 2015 | 47 |
| Cindy Dunkle | Chief People Officer | Senior Management | - | - |
| Carole Ho | Head - Development; Chief Medical Officer | Senior Management | 2015 | 50 |
| Joe Lewcock | Chief Scientific Officer; Head - Discovery | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward